Zug, Switzerland
Pharvaris, founded in 2015, is a Switzerland-based clinical-stage company at the forefront of developing oral treatments for bradykinin-mediated diseases such as hereditary angioedema (HAE). The company’s slogan, "Pioneering science for patient choice", reflects its dedication to innovative therapeutic options.
Specializing in the biotechnology, healthcare, life sciences, and pharmaceutical industries, Pharvaris focuses on oral bradykinin-B2-receptor antagonists that offer new alternatives to injectable therapies. This strategic approach aims to improve patient accessibility and adherence to treatment regimens.
What sets Pharvaris apart is its team, which reunites key players behind the discovery of icatibant, a previously approved HAE treatment. This expertise lends credibility to their ongoing efforts with novel, orally available small molecules.
Recently, Pharvaris secured a $67.83M post-IPO equity investment from General Atlantic (as of 01 December 2025), positioning it for continued growth and development within its target market.
